Adults with a BMI of 35 to 39 and a serious related condition receive less under the composite rule, and the NU506 Unit 5 analysis argues for a risk-based line instead. Searches like "nu 506 unit 5 assignment example", "nu506 unit 5 sample" and "nu506 unit 5 example" land here.
A Line Drawn at a Body Mass Index of 40: An Allocation Ethics Analysis of a State Medicaid Rule for Semaglutide, and a Better Line
[Student Name]
Purdue University Global
NU506: Health Policy, Ethical, and Legal Perspectives of the Health Care System
Unit 5 Assignment
[Instructor Name]
[Date]
The state, its budget and its enrollment figures are composite; the law, trials and ethical framework cited are published.
The Rule
Federal Medicaid law allows states to exclude drugs used for weight loss from coverage, so any coverage a state offers is its own choice (42 U.S.C. § 1396r-8, 2024). The composite state chose limited coverage under a fixed annual budget. Adults qualify for semaglutide 2.4 mg if their body mass index is 40 or more and they have at least one weight-related condition, such as type 2 diabetes, hypertension or sleep apnea. Coverage ends after 24 months, and no one may restart. The budget line assumes about [4,200] people treated at any time.
The rule has a logic. A BMI of 40 identifies people with severe obesity, among whom risks are high. A time limit caps spending. A fixed budget protects other Medicaid services. Judged on its own terms, it is an attempt to spend a limited sum on the people who seem to need it most.
Who the Rule Shortchanges
Three groups lose under this rule, each for a clinical reason.
Adults with a BMI of 35 to 39 and serious weight-related disease. A 52-year-old woman with a BMI of 37, sleep apnea and prediabetes is excluded, though her risks are substantial and semaglutide lowers weight in people like her. In a trial of adults with established cardiovascular disease and a BMI of 27 or more without diabetes, semaglutide reduced major cardiovascular events by about a fifth compared with placebo (Lincoff et al., 2023). The BMI cutoff excludes many people at high cardiometabolic risk.
People who respond well and reach the 24-month limit. Weight returns after the drug stops. In a withdrawal trial, participants who switched to placebo after 20 weeks of semaglutide regained weight while those who continued kept losing (Rubino et al., 2021). In the extension of another trial, participants regained about two-thirds of their lost weight in the year after stopping (Wilding et al., 2022). A fixed time limit therefore withdraws treatment from exactly the people for whom it is working, and much of what was spent on them is lost.
Adults of Asian descent. An expert consultation for the World Health Organization found that Asian populations carry higher risks of type 2 diabetes and cardiovascular disease at lower BMI than European populations, and it proposed lower action points (WHO Expert Consultation, 2004). A single cutoff of 40 applied to everyone reaches Asian adults at a later point in their risk than it reaches others.
Testing the Rule Against Allocation Principles
Persad et al. (2009) group principles for allocating scarce medical interventions into four families: treating people equally, favoring the worst off, maximizing total benefits, and promoting and rewarding social usefulness. They argue that no single principle is sufficient and recommend combining several. Three are relevant here.
Sickest first, a form of favoring the worst off. BMI is a poor proxy for sickness. A person with a BMI of 41 and no complications other than mild hypertension qualifies; a person with a BMI of 37, sleep apnea and prediabetes does not. The rule favors the heaviest, not the sickest.
Maximizing benefit per dollar. The time limit undermines this principle directly, because it stops treatment when benefit is being realized and lets weight return, so money spent in the first two years buys less lasting benefit than it could. The cutoff also ignores evidence that benefit is large at lower BMI when risk is high.
Treating people equally, for example by lottery or first come first served. The rule is not a lottery; it sorts by a single measure. Equal chances would at least treat every eligible person alike, but the rule's category of eligible people is drawn on a poor measure to begin with.
On each of these principles the existing rule does poorly: it is a weak proxy for sickness, a weak proxy for benefit and not an equal-chance mechanism.
A Replacement Rule
Eligibility by a risk score that combines BMI with specific conditions, and no fixed limit for people who respond.
Eligibility: a BMI of 35 or more with at least two weight-related conditions, or a BMI of 30 or more with established cardiovascular disease, with cutoffs lowered by 2.5 points for adults of Asian descent. Continuation: people who have lost at least 5 percent of their starting weight at six months continue as long as they respond; those who do not respond stop, and their place goes to someone new.
This rule is defended on prioritarian grounds, giving extra weight to those at highest risk, combined with a benefit test that stops treatment where it is not working. It also uses money better, because it keeps treating those who benefit and stops treating those who do not.
Price. The replacement roughly doubles the eligible population, to about [8,900] adults. Assuming the same net cost per person, about $[6,000] a year after rebates, and that about half of eligible adults start treatment, annual spending would rise from about $[25] million to about $[27] million in the first year, because nonresponders stop at six months, and to more in later years as responders stay on. The state would need either a larger budget line or a waiting list ordered by risk score.
Who Gets Less Under the New Line
The replacement has losers too, and they should be named before it is recommended. People with a BMI of 40 or more and a single mild condition, who qualify today, may fall below the new risk threshold or wait longer. People who lose less than 5 percent of their weight at six months will be stopped, though some might have responded later. And if the budget does not grow, a waiting list ordered by risk means some eligible people will wait a long time. The replacement moves resources toward higher risk and demonstrated benefit, which is defensible, but it is not free of cost to real people.
At the Clinic
A primary care nurse is often the person who explains a denial. Under the current rule, the nurse tells the 52-year-old with a BMI of 37 that she does not qualify because her BMI is below 40, a reason that makes no clinical sense to her. Under the replacement rule, the nurse can explain that coverage depends on her risk from sleep apnea and prediabetes and on whether the drug works for her, which is a reason she can understand even if she still disagrees with the result.
References
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://doi.org/10.1056/NEJMoa2307563
Persad, G., Wertheimer, A., & Emanuel, E. J. (2009). Principles for allocation of scarce medical interventions. The Lancet, 373(9661), 423-431. https://doi.org/10.1016/S0140-6736(09)60137-9
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224
42 U.S.C. § 1396r-8 (2024).
WHO Expert Consultation. (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet, 363(9403), 157-163. https://doi.org/10.1016/S0140-6736(03)15268-3
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. https://doi.org/10.1111/dom.14725
How this NU506 Unit 5 example is structured
The rule is described neutrally before anyone is named as losing under it, so the reader can judge it on its own terms. The losers section comes second and carries the analysis the course emphasizes: each group is described with the clinical reason its exclusion matters, not simply its size. The principles section then tests the existing rule against each allocation principle in turn and shows that the BMI cutoff serves none of them well, being a poor proxy for sickness, a poor proxy for benefit and not a lottery. The replacement, eligibility by a risk score combining BMI with specific conditions and no fixed limit for responders, is defended on prioritarian grounds, and the analysis prices it. Then it says who gets less once the new line is drawn: people at lower risk who would still benefit. That admission comes before the clinic section, not after it.
Get an NU506 Unit 5 example written to your instructions
Any scarce-resource rule will work for NU506 Unit 5, a coverage limit, a waitlist, a staffing formula, provided someone ends up with less because of it. Tell us the rule and your section's grading criteria. A free first analysis follows in 24-48h, naming who is left out, applying the principles to that rule and admitting who loses under its replacement. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU506 Unit 5 questions, answered
Which allocation principles are expected?
Commonly the major families: treating the worst off first, maximizing total benefit, equal chances through lotteries or queues, and rewarding social usefulness, usually to reject it. The 2009 Lancet paper by Persad, Wertheimer and Emanuel groups them clearly. Your course text may name its own set; use those terms if it does, and apply each to the rule under study.
Does the analysis have to propose a new rule?
Not always, but most prompts reward a position. Defending the existing rule is acceptable if you show who it leaves out and give a principled reason for accepting that. Proposing a replacement requires naming who loses out under it, since every allocation rule written under scarcity leaves someone with less than they need.
How should cost figures be handled?
Use them to show scale, with a date and source, and treat them as approximate. Drug prices, rebates and state budgets change quickly and are often confidential. A rough estimate of what the proposed rule would cost, set against the current budget line, is enough to show the proposal was priced rather than wished into existence.